Work

A phase I dose-escalation study of a first-in-class HIF1 and HIF2 dual inhibitor R01 in patients with advanced tumors.

Year: 2025

Type: conference-abstract

Study design: Clinical Trial

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.e15097

Authors: Shan Zeng, Guanghai Dai, Hairong Jiang, Ru Jia, Qun Qin, Yiping Liu, Youhong Tang, Feng Chen, Yao Xu, Jing Zhang, Qingjuan Yang, Yunhong Mei, Chunlai Mi, Qian Tang, He Li, Baiyan Liu, Siyi Zhang, Haiyong Wang, Ruiqiong Ran

Institutions: Central South University, Xiangya Hospital Central South University, Chinese PLA General Hospital, Chinese People's Liberation Army

Language: English

Topic: Cancer, Hypoxia, and Metabolism

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410816166

Cites:

Cited by:

Related to: 10